^
BIOMARKER:

ALK positive

i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Entrez ID:
ALK positive
NHL
crizotinib
Sensitive: A1 - Approval
ASH 2021 - 3 weeks
ALK positive
NHL
alectinib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
ALK positive
NHL
ceritinib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
ALK positive
NHL
CART-30
Resistant: C4 – Case Studies
ASH 2021 - 3 weeks
ALK positive
NSCLC
lorlatinib
Sensitive: A1 - Approval
ALK positive
NSCLC
alectinib
Sensitive: A1 - Approval
ALK positive
NSCLC
brigatinib
Sensitive: A1 - Approval
ALK positive
NSCLC
crizotinib
Sensitive: A1 - Approval
ALK positive
NSCLC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
ALK positive
NSCLC
ceritinib
Sensitive: A1 - Approval
ALK positive
NSCLC
atezolizumab
Sensitive: A1 - Approval
ALK positive
Peripheral T-cell Lymphoma
crizotinib
Sensitive: A2 - Guideline
ALK positive
NSCLC
X-396
Sensitive: B - Late Trials
ALK positive
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: B - Late Trials
ALK positive
NHL
brentuximab vedotin
Sensitive: B - Late Trials
ALK positive
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: B - Late Trials
ALK positive
Lymphoma
crizotinib
Sensitive: B - Late Trials
ALK positive
Lung Non-Squamous Non-Small Cell Cancer
crizotinib
Sensitive: B - Late Trials
ALK positive
LUAD
lorlatinib
Sensitive: C1 - Off-label
ALK positive
Lung Non-Small Cell Squamous Cancer
brigatinib
Sensitive: C1 - Off-label
ALK positive
NSCLC
AUY922
Sensitive: C2 – Inclusion Criteria
ALK positive
NSCLC
SAF-189
Sensitive: C2 – Inclusion Criteria
ALK positive
NSCLC
pembrolizumab
Sensitive: C2 – Inclusion Criteria
ALK positive
Neuroblastoma
crizotinib
Sensitive: C3 – Early Trials
ALK positive
NSCLC
TQ-B3139
Sensitive: C3 – Early Trials
ALK positive
NSCLC
sintilimab
Sensitive: C3 – Early Trials
ALK positive
NSCLC
PD-L1 inhibitor
Resistant: C3 – Early Trials
ALK positive
LUAD
pemetrexed
Sensitive: C3 – Early Trials
ALK positive
Solid Tumor
TQ-B3101
Sensitive: C3 – Early Trials
ALK positive
Lung Non-Squamous Non-Small Cell Cancer
X-396
Sensitive: C3 – Early Trials
ALK positive
Solid Tumor
TPX-0005
Sensitive: C3 – Early Trials
ALK positive
NSCLC
atezolizumab + alectinib
Sensitive: C3 – Early Trials
ALK positive
NSCLC
crizotinib + alectinib
Sensitive: C3 – Early Trials
ALK positive
NSCLC
trametinib + ceritinib
Sensitive: C3 – Early Trials
ALK positive
NSCLC
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
ALK positive
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: C4 – Case Studies
ALK positive
CLL
ibrutinib
Sensitive: C4 – Case Studies
ALK positive
LUAD
ruxolitinib
Sensitive: C4 – Case Studies
ALK positive
LUAD
alectinib + brigatinib
Resistant: C4 – Case Studies
ALK positive
T Cell Non-Hodgkin Lymphoma
ceritinib
Sensitive: D – Preclinical
ALK positive
NSCLC
ADX-1612
Sensitive: D – Preclinical
ALK positive
Neuroblastoma
CAR-T immunotherapy
Sensitive: D – Preclinical
ALK positive
T Cell Non-Hodgkin Lymphoma
CFT7455
Sensitive: D – Preclinical
ALK positive
NHL
crizotinib + trametinib
Sensitive: D – Preclinical